

Veterinary Pain Management Drugs Market - 2023-2031

<https://marketpublishers.com/r/V7BFC416AE25EN.html>

Date: September 2025

Pages: 220

Price: US\$ 2,999.00 (Single User License)

ID: V7BFC416AE25EN

Abstracts

The Veterinary Pain Management Drugs Market was valued at US\$ 2.06 billion in 2023 and is anticipated to reach US\$ 3.00 billion by 2031, at a CAGR of 0.048 from 2026 to 2032.

The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Veterinary Pain Management Drugs Market.

This report delivers a comprehensive overview of the Veterinary Pain Management Drugs Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Veterinary Pain Management Drugs Market. The Veterinary Pain Management Drugs Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for 2023–2031.

Veterinary Pain Management Drugs Market Scope:

By Drug Type

NSAIDS

Opioids

Local Anesthetics

Alpha-2 Agonists

Disease Modified Osteoarthritis Drugs (DMOAD)

By Route of Administration

Oral

Parenteral

Topical

By Animal

Companion Animal

Livestock

By Application

Postoperative Pain

Joint Pain

Cancer

Other

By Distribution Channel

Veterinary Hospitals & Clinics

Retail Pharmacies

Online Pharmacies

Key Players

Dechra Pharmaceuticals

Zoetis

Elanco

Boehringer Ingelheim

Vetoquinol S.A.

Ceva Sante Animale S.A.

Bayer AG

Merck Animal Health

Norbrook Laboratories

Chanelle Pharma

Virbac

Assisi Animal Health

Major Highlights

This report delivers a comprehensive overview of the Veterinary Pain Management Drugs Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the

current market, and make informed business decisions regarding Veterinary Pain Management Drugs Market. The Veterinary Pain Management Drugs Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for 2023–2031.

This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Regional Analysis:

North America (U.S., Canada, Mexico)

Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

South America (Colombia, Brazil, Argentina, Rest of South America)

Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Partner Identification

Increase Your Customer Base by 3X using our Partner Identification tool

Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.

Identify high potential M&A targets based on synergies, market positioning and growth trajectory.

Prioritize partners by strategic fit rather than general capability.

Why Choose DataM?

Data-Driven Insights: Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.

Post-Purchase Support and Expert Analyst Consultations: As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.

White Papers and Case Studies: Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.

Annual Updates on Purchased Reports: As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions apply.

Specialized Focus on Emerging Markets: DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. This approach equips our clients with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.

Value of DataM Reports: Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.

Target Audience 2026

Manufacturers/ Buyers

Industry Investors/Investment Bankers

Research Professionals

Emerging Companies

Contents

1. METHODOLOGY AND SCOPE

- 1.1. Research methodology
- 1.2. Research Objective and Scope of the Report

2. MARKET DEFINITION AND OVERVIEW

3. EXECUTIVE SUMMARY

- 3.1. Market Snippet by Drugs
- 3.2. Market Snippet by Route of Administration
- 3.3. Market Snippet by Animal
- 3.4. Market Snippet by Application
- 3.5. Market Snippet by Distribution Channel
- 3.6. Market Snippet by Region

4. MARKET DYNAMICS

- 4.1. Market Impacting Factors
- 4.2. Drivers
 - 4.2.1. Rising Prevalence of Painful and Inflammatory Diseases in Animals
 - 4.2.2. Increasing Initiatives towards Animal Healthcare
 - 4.2.3. Increasing number of companion animal ownership
- 4.3. Restraints
 - 4.3.1. Side Effects Associated with Drugs
 - 4.3.2. Changes in Distribution Channel
- 4.4. Opportunity
- 4.5. Impact Analysis

5. INDUSTRY ANALYSIS

- 5.1. Porter's Five Forces Analysis
- 5.2. Supply Chain Analysis
- 5.3. Regulatory Analysis
- 5.4. Pricing Analysis

6. COVID-19 ANALYSIS

- 6.1. Analysis of Covid-19 on the Market
 - 6.1.1. Before COVID-19 Market Scenario
 - 6.1.2. Present COVID-19 Market Scenario
 - 6.1.3. After COVID-19 or Future Scenario
- 6.2. Pricing Dynamics Amid Covid-19
- 6.3. Demand-Supply Spectrum
- 6.4. Government Initiatives Related to the Market During Pandemic
- 6.5. Manufacturers Strategic Initiatives
- 6.6. Conclusion

7. BY DRUG TYPE

- 7.1. Introduction
 - 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type Segment
 - 7.1.2. Market Attractiveness Index, By Drug Type Segment
- 7.2. NSAIDS*
 - 7.2.1. Introduction
 - 7.2.2. Market Size Analysis, Y-o-Y Growth Analysis (%)
 - 7.2.3. Meloxicam
 - 7.2.4. Deracoxib
 - 7.2.5. Carprofen
 - 7.2.6. Etodolac
 - 7.2.7. Firocoxib
 - 7.2.8. Others
- 7.3. Opioids
 - 7.3.1. Morphine
 - 7.3.2. Codeine
 - 7.3.3. Fentanyl
 - 7.3.4. Buprenorphine
 - 7.3.5. Others
- 7.4. Local Anesthetics
 - 7.4.1. Lidocaine
 - 7.4.2. Bupivacaine
 - 7.4.3. Mepivacaine
 - 7.4.4. Others
- 7.5. Alpha-2 Agonists
 - 7.5.1. Medetomidine
 - 7.5.2. Xylazine

7.5.3. Romifidine

7.5.4. Others

7.6. Disease Modified Osteoarthritis Drugs (DMOAD)

7.6.1. Others

8. BY ROUTE OF ADMINISTRATION

8.1. Introduction

8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration Segment

8.1.2. Market Attractiveness Index, By Route of Administration Segment

8.2. Oral*

8.2.1. Introduction

8.2.2. Market Size Analysis, Y-o-Y Growth Analysis (%)

8.3. Parenteral

8.4. Topical

9. BY ANIMAL

9.1. Introduction

9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Animal Segment

9.1.2. Market Attractiveness Index, By Animal Segment

9.2. Companion Animal*

9.2.1. Introduction

9.2.2. Market Size Analysis, Y-o-Y Growth Analysis (%)

9.2.3. Dogs

9.2.4. Cats

9.2.5. Horses

9.2.6. Other Companion Animals

9.3. Livestock

9.3.1. Cattle

9.3.2. Swine

9.3.3. Other Livestock Animals

10. BY APPLICATION

10.1. Introduction

10.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application Segment

10.1.2. Market Attractiveness Index, By Application Segment

10.2. Postoperative Pain*

10.2.1. Introduction

10.2.2. Market Size Analysis, Y-o-Y Growth Analysis (%)

10.3. Joint Pain

10.3.1. Osteoarthritis

10.3.2. Musculoskeletal Disorders

10.4. Cancer

10.5. Other

11. BY DISTRIBUTION CHANNEL

11.1. Introduction

11.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel Segment

11.1.2. Market Attractiveness Index, By Distribution Channel Segment

11.2. Veterinary Hospitals & Clinics*

11.2.1. Introduction

11.2.2. Market Size Analysis, Y-o-Y Growth Analysis (%)

11.3. Retail Pharmacies

11.4. Online Pharmacies

12. BY REGION

12.1. Introduction

12.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region

12.1.2. Market Attractiveness Index, By Region

12.2. North America

12.2.1. Introduction

12.2.2. Key Region-Specific Dynamics

12.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type

12.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Animal

12.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration

Administration

12.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application

12.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

12.2.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Countries

12.2.8.1. U.S.

12.2.8.2. Canada

12.2.8.3. Mexico

12.3. Europe

12.3.1. Introduction

12.3.2. Key Region-Specific Dynamics

12.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type

12.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Animal

12.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of

Administration

12.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application

12.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

12.3.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Countries

12.3.8.1. Germany

12.3.8.2. U.K.

12.3.8.3. France

12.3.8.4. Italy

12.3.8.5. Spain

12.3.8.6. Rest of Europe

12.4. South America

12.4.1. Introduction

12.4.2. Key Region-Specific Dynamics

12.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type

12.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Animal

12.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of

Administration

12.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application

12.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

12.4.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Countries

12.4.8.1. Brazil

12.4.8.2. Argentina

12.4.8.3. Rest of South America

12.5. Asia Pacific

12.5.1. Introduction

12.5.2. Key Region-Specific Dynamics

12.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type

12.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Animal

12.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of

Administration

12.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application

12.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

12.5.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Countries

12.5.8.1. China

12.5.8.2. India

12.5.8.3. Japan

12.5.8.4. Australia

12.5.8.5. Rest of Asia Pacific

12.6. The Middle East and Africa

12.6.1. Introduction

12.6.2. Key Region-Specific Dynamics

12.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type

12.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Animal

12.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration

12.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application

12.6.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

13. COMPETITIVE LANDSCAPE

13.1. Competitive Scenario

13.2. Key Strategies adopted by Manufacturers

13.3. Market Positioning/Share Analysis

13.4. Product Benchmarking

14. COMPANY PROFILES

14.1. Dechra Pharmaceuticals*

14.1.1. Company overview

14.1.2. Procedure portfolio and description

14.1.3. Key highlights

14.1.4. Financial overview

14.2. Zoetis

14.3. Elanco

14.4. Boehringer Ingelheim

14.5. Vetoquinol S.A.

14.6. Ceva Sante Animale S.A.

14.7. Bayer AG

14.8. Merck Animal Health

14.9. Norbrook Laboratories

14.10. Chanelle Pharma

14.11. Virbac

14.12. Assisi Animal Health

15. DATAM INTELLIGENCE

15.1. Appendix

15.2. About Us and Services

15.3. Contact Us

I would like to order

Product name: Veterinary Pain Management Drugs Market - 2023-2031

Product link: <https://marketpublishers.com/r/V7BFC416AE25EN.html>

Price: US\$ 2,999.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/V7BFC416AE25EN.html>